However, checkpoint inhibitor treatment targeting PD1 and CTLA4 has been tested in ovarian cancer patients with sparse response rates [22,25,26,52], leaving TIGIT as a remaining potential target for treating HGSC recurrence [53]. This evidence concerns the gene TIGIT and ovarian cancer.